Latest From Aptinyx Inc.
After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.
Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.
Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- Naurex spin-off
- Enarex Inc.
- Eranix Inc.
- North America
- Company Type
- Parent & Subsidiaries
- Aptinyx Inc.
- Senior Management
Norbert G Riedel, PhD, Pres. & CEO
Ashish Khanna, CFO & CBO
Joseph R Moskal, PhD, CSO
Torsten M Madsen, MD, PhD, CMO
Andrew Kidd, Chief Commercial Officer
Cassia Cearley, PhD, VP, Research
David R Houck, PhD, Chief Dev. Officer
- Contact Info
Phone: (847) 871-0377
909 Davis St.
Evanston, IL 60201
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.